Qprotyn is a Delaware biotech corporation based in Cambridge, MA and is bringing to market a patented viscosity-reduction, formulation platform called HILOPRO®.
HILOPRO® enables high-dose, large molecule monoclonal antibodies to move from IV administration to subcutaneous (SubQ) injection.
Using only two GRAS excipients, HILOPRO® delivers low-volume formulations with concentrations greater than 225mg/mL while maintaining a viscosity less than 20 cP.
Naturally, this introduces tremendous patient benefits in terms of comfort and convenience and enables innovator and biosimilar mAbs to enhance their marketability.
Upgrade your IV mAb to SubQ with Qprotyn | Patients will thank you for getting under their skin!
Company Details
- Employees
- 2
- Founded
- -
- Address
- 125 Cambridge Park Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.qprotyn.com
- Keywords
- IndiaPharmaHub.
- HQ
- Cambridge, Massachusetts
Qprotyn Questions
Qprotyn's website is http://www.qprotyn.com
Qprotyn's LinkedIn profile is https://www.linkedin.com/company/qprotyn
Qprotyn has
2 employees.
View email and phone details for 2
employees at Qprotyn.
Qprotyn's industry is
Biotechnology Research
Qprotyn's top competitors are
Krooked Korner,
Amaterasu Lifesciences Llp,
Indiapharmahub,
Dorra Pharma Group,
Audax Sports,
Yuyu Pharma Us,
Wetranslate,
Yuyu Pharma,
Anzen Exports Pvt. Ltd.,
Ragasphere.
Qprotyn's categories are Biotechnology Research
Qprotyn's founding year is 2021
